Skip to content

Exercise in Sjogren, Myositis and Takayasu's Arteritis

Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01501019
Enrollment
60
Registered
2011-12-29
Start date
2011-10-31
Completion date
Unknown
Last updated
2016-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myositis, Primary Sjogren´s Syndrome

Brief summary

Exercise may improve physical capacity and health parameters in Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis. Therefore, this study aims to investigate the role of an exercise training program in patients with Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.

Interventions

OTHERExercise training

Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity. Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity. Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity.

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Physically inactive * Stable drugs regime for at least three months

Exclusion criteria

* Other rheumatic diseases * Physical disability that prevent the patient to perform the physical tests * Severe pulmonary disease

Design outcomes

Primary

MeasureTime frameDescription
Aerobic CapacityTwelve weeksMaximum Oxygen Consumption (VO2Max)
Muscle strengthTwelve weeks
Quality of lifeTwelve weeks

Secondary

MeasureTime frameDescription
Serum anti-inflammatory cytokinesTwelve weeksInterleukin-10
Serum pro-inflammatory cytokinesTwelve weeksInterleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a)
Serum inflammatory markersTwelve weekserythrocyte sedimentation rate (ESR), c-reactive protein (CRP), aldolase

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026